Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the safety and effectiveness of a single dose of NTLA-2001, given as an intravenous infusion, compared to a placebo in people with transthyretin amyloidosis with cardiomyopathy ATTR-CM. This condition affects the heart due to amyloid deposits, and the study aims to understand how the treatment impacts heart-related outcomes over time. The trial is a multinational, double-blind, placebo-controlled study involving about 1200 participants. Participants will be randomly assigned to receive either one infusion of NTLA-2001 or a placebo infusion of normal saline. The treatments are administered once intravenously. The studys main focus is to assess cardiovascular outcomes including mortality and events over a period estimated between 18 months and up to about 5 years. Secondary assessments will measure changes in serum transthyretin levels and health status scores related to heart failure at baseline and after 18 months. During the study, participants will be monitored for cardiovascular health and heart failure symptoms. Blood samples will be collected to check biomarker changes, and health questionnaires will be completed to assess quality of life. The trial includes long-term follow-up to capture important heart-related events and safety information. The total duration of participation may vary, with the primary outcome measured over a multi-year period depending on event rates.